Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination
- PMID: 26795730
- PMCID: PMC4722756
- DOI: 10.1186/s13046-016-0295-1
Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination
Abstract
Background: Dendritic cells (DCs) have been used successfully in clinical pilot studies. However, tumor-specific immunity and clinical responses were only induced in certain cancer patients. It has been well documented that immunotherapy efficacy can be optimized for responses using antigen pulsing.
Methods: The human laryngeal squamous cell cancer (LSCC) cell line SNU899 was used to evaluate the in vitro anti-tumor efficacy of three different preparations of dendritic cell (DC) vaccines consisting of either whole tumor cells or their derivatives including: i) DCs pulsed with a tumor cell supernatant (DC-TCS), ii) DCs pulsed with whole-cell tumor stressed lysate (DC-TSL), and iii) DCs pulsed with irradiated tumor cells (DC-ITC).
Results: Our results showed that DC-TSL is an effective source of tumor-associated antigens (TAAs) for pulsing DCs. DC-TSL induced the highest expansion of TAA-specific T cells, the strongest Th1 cytokine response, and the most potent cytotoxic T lymphocyte (CTL) activity. DC-TCS and DC-ITC inhibited T cell activation but induced a certain extent of CTL activity.
Conclusions: These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal cancer than other antigen-loading strategies using whole tumor cell materials. This strategy provides an alternative approach for DC-based immunotherapy for laryngeal cancer.
Figures





Similar articles
-
Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.Oncol Rep. 2006 Dec;16(6):1317-24. Oncol Rep. 2006. PMID: 17089056
-
Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.Cancer Res. 2001 Sep 1;61(17):6445-50. Cancer Res. 2001. PMID: 11522639
-
Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.Cancer Immunol Immunother. 2002 Aug;51(6):299-310. doi: 10.1007/s00262-002-0284-4. Epub 2002 Jun 14. Cancer Immunol Immunother. 2002. PMID: 12111118 Free PMC article.
-
Tumor cell lysates as immunogenic sources for cancer vaccine design.Hum Vaccin Immunother. 2014;10(11):3261-9. doi: 10.4161/21645515.2014.982996. Hum Vaccin Immunother. 2014. PMID: 25625929 Free PMC article. Review.
-
Advances in dendritic cell-based vaccine of cancer.Cancer Biother Radiopharm. 2002 Dec;17(6):601-19. doi: 10.1089/108497802320970217. Cancer Biother Radiopharm. 2002. PMID: 12537664 Review.
Cited by
-
IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.Front Oncol. 2021 May 5;11:648293. doi: 10.3389/fonc.2021.648293. eCollection 2021. Front Oncol. 2021. PMID: 34026621 Free PMC article.
-
Dendritic Cell Vaccine Loaded with MG-7 Antigen Induces Cytotoxic T Lymphocyte Responses against Gastric Cancer.J Healthc Eng. 2022 Apr 18;2022:1964081. doi: 10.1155/2022/1964081. eCollection 2022. J Healthc Eng. 2022. PMID: 35480145 Free PMC article.
-
Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.Cancer Immunol Immunother. 2019 Jan;68(1):121-130. doi: 10.1007/s00262-018-2257-2. Epub 2018 Oct 10. Cancer Immunol Immunother. 2019. PMID: 30306202 Free PMC article. Clinical Trial.
-
Mechanisms of Jisheng-Wumei tablet in laryngeal cancer treatment: a network pharmacology analysis of baicalein's targeting of cytochrome C for laryngeal cancer inhibition.Discov Oncol. 2025 Jun 7;16(1):1027. doi: 10.1007/s12672-025-02829-0. Discov Oncol. 2025. PMID: 40481938 Free PMC article.
-
The MicroRNA-106a/20b Strongly Enhances the Antitumour Immune Responses of Dendritic Cells Pulsed with Glioma Stem Cells by Targeting STAT3.J Immunol Res. 2022 Sep 15;2022:9721028. doi: 10.1155/2022/9721028. eCollection 2022. J Immunol Res. 2022. PMID: 36157880 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources